vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and Lucid Diagnostics Inc. (LUCD). Click either name above to swap in a different company.

INVO Fertility, Inc. is the larger business by last-quarter revenue ($1.8M vs $1.2M, roughly 1.5× Lucid Diagnostics Inc.). INVO Fertility, Inc. runs the higher net margin — -150.5% vs -858.5%, a 708.0% gap on every dollar of revenue. On growth, INVO Fertility, Inc. posted the faster year-over-year revenue change (22.6% vs 3.3%). Over the past eight quarters, INVO Fertility, Inc.'s revenue compounded faster (12.8% CAGR vs 7.9%).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics firm focused on non-invasive screening tests for upper gastrointestinal diseases, including early detection of esophageal cancer and pre-cancerous lesions. It mainly serves healthcare providers and clinical partners across the United States, targeting at-risk patient populations.

IVF vs LUCD — Head-to-Head

Bigger by revenue
IVF
IVF
1.5× larger
IVF
$1.8M
$1.2M
LUCD
Growing faster (revenue YoY)
IVF
IVF
+19.3% gap
IVF
22.6%
3.3%
LUCD
Higher net margin
IVF
IVF
708.0% more per $
IVF
-150.5%
-858.5%
LUCD
Faster 2-yr revenue CAGR
IVF
IVF
Annualised
IVF
12.8%
7.9%
LUCD

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
IVF
IVF
LUCD
LUCD
Revenue
$1.8M
$1.2M
Net Profit
$-2.6M
$-10.4M
Gross Margin
Operating Margin
-93.1%
-971.0%
Net Margin
-150.5%
-858.5%
Revenue YoY
22.6%
3.3%
Net Profit YoY
-62.2%
16.0%
EPS (diluted)
$-0.77
$-0.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
LUCD
LUCD
Q3 25
$1.8M
$1.2M
Q2 25
$1.9M
$1.2M
Q1 25
$1.6M
$828.0K
Q4 24
$1.7M
$1.2M
Q3 24
$1.4M
$1.2M
Q2 24
$1.8M
$976.0K
Q1 24
$1.6M
$1.0M
Q4 23
$1.4M
$1.0M
Net Profit
IVF
IVF
LUCD
LUCD
Q3 25
$-2.6M
$-10.4M
Q2 25
$-5.3M
$-4.4M
Q1 25
$-17.4M
$-26.9M
Q4 24
$-3.6M
$-11.5M
Q3 24
$-1.6M
$-12.4M
Q2 24
$-2.2M
$-11.0M
Q1 24
$-1.6M
$-10.6M
Q4 23
$-2.0M
$-10.8M
Gross Margin
IVF
IVF
LUCD
LUCD
Q3 25
Q2 25
Q1 25
35.2%
Q4 24
41.4%
Q3 24
31.0%
Q2 24
53.1%
Q1 24
45.3%
Q4 23
33.0%
Operating Margin
IVF
IVF
LUCD
LUCD
Q3 25
-93.1%
-971.0%
Q2 25
-160.4%
-978.8%
Q1 25
-1042.1%
-1508.1%
Q4 24
-202.0%
-1033.8%
Q3 24
-90.7%
-997.8%
Q2 24
-100.9%
-1146.7%
Q1 24
-95.7%
-1078.1%
Q4 23
-109.2%
-1101.3%
Net Margin
IVF
IVF
LUCD
LUCD
Q3 25
-150.5%
-858.5%
Q2 25
-283.6%
-381.7%
Q1 25
-1060.1%
-3249.8%
Q4 24
-211.3%
-964.2%
Q3 24
-113.8%
-1055.5%
Q2 24
-122.2%
-1127.6%
Q1 24
-101.3%
-1060.1%
Q4 23
-144.4%
-1041.3%
EPS (diluted)
IVF
IVF
LUCD
LUCD
Q3 25
$-0.77
$-0.10
Q2 25
$-13.30
$-0.08
Q1 25
$-12.53
$-0.52
Q4 24
$14.86
$-0.17
Q3 24
$-15.11
$-0.25
Q2 24
$-22.39
$-0.23
Q1 24
$-7.55
$-0.40
Q4 23
$-59.51
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
LUCD
LUCD
Cash + ST InvestmentsLiquidity on hand
$47.3M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$5.8M
$25.8M
Total Assets
$18.8M
$53.2M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
LUCD
LUCD
Q3 25
$47.3M
Q2 25
$31.1M
Q1 25
$25.2M
Q4 24
$22.4M
Q3 24
$14.5M
Q2 24
$24.9M
Q1 24
$24.8M
Q4 23
$18.9M
Total Debt
IVF
IVF
LUCD
LUCD
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Q4 23
Stockholders' Equity
IVF
IVF
LUCD
LUCD
Q3 25
$5.8M
$25.8M
Q2 25
$2.6M
$7.9M
Q1 25
$3.3M
$-5.4M
Q4 24
$12.7M
$5.4M
Q3 24
$-23.3K
$6.3M
Q2 24
$1.4M
$16.0M
Q1 24
$10.2K
$11.9M
Q4 23
$892.8K
$-2.3M
Total Assets
IVF
IVF
LUCD
LUCD
Q3 25
$18.8M
$53.2M
Q2 25
$19.3M
$38.7M
Q1 25
$31.7M
$32.8M
Q4 24
$46.4M
$30.7M
Q3 24
$17.0M
$22.6M
Q2 24
$17.8M
$34.1M
Q1 24
$17.3M
$32.0M
Q4 23
$18.5M
$27.3M
Debt / Equity
IVF
IVF
LUCD
LUCD
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
LUCD
LUCD
Operating Cash FlowLast quarter
$-1.8M
$-10.9M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-101.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
LUCD
LUCD
Q3 25
$-1.8M
$-10.9M
Q2 25
$-1.7M
$-10.5M
Q1 25
$-3.5M
$-12.5M
Q4 24
$-617.4K
$-9.9M
Q3 24
$-640.8K
$-10.2M
Q2 24
$-1.5M
$-11.5M
Q1 24
$-260.6K
$-12.6M
Q4 23
$-714.9K
$-10.0M
Free Cash Flow
IVF
IVF
LUCD
LUCD
Q3 25
$-1.8M
Q2 25
$-1.7M
Q1 25
$-3.6M
Q4 24
$-696.3K
Q3 24
Q2 24
$-1.5M
Q1 24
$-310.3K
Q4 23
FCF Margin
IVF
IVF
LUCD
LUCD
Q3 25
-101.6%
Q2 25
-92.6%
Q1 25
-216.9%
Q4 24
-40.6%
Q3 24
Q2 24
-82.3%
Q1 24
-19.7%
Q4 23
Capex Intensity
IVF
IVF
LUCD
LUCD
Q3 25
0.5%
Q2 25
0.5%
Q1 25
0.9%
Q4 24
4.6%
Q3 24
0.0%
Q2 24
3.0%
Q1 24
3.2%
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons